395 related articles for article (PubMed ID: 29929783)
1. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Gaudinski MR; Coates EE; Novik L; Widge A; Houser KV; Burch E; Holman LA; Gordon IJ; Chen GL; Carter C; Nason M; Sitar S; Yamshchikov G; Berkowitz N; Andrews C; Vazquez S; Laurencot C; Misasi J; Arnold F; Carlton K; Lawlor H; Gall J; Bailer RT; McDermott A; Capparelli E; Koup RA; Mascola JR; Graham BS; Sullivan NJ; Ledgerwood JE;
Lancet; 2019 Mar; 393(10174):889-898. PubMed ID: 30686586
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
Playford EG; Munro T; Mahler SM; Elliott S; Gerometta M; Hoger KL; Jones ML; Griffin P; Lynch KD; Carroll H; El Saadi D; Gilmour ME; Hughes B; Hughes K; Huang E; de Bakker C; Klein R; Scher MG; Smith IL; Wang LF; Lambert SB; Dimitrov DS; Gray PP; Broder CC
Lancet Infect Dis; 2020 Apr; 20(4):445-454. PubMed ID: 32027842
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
8. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
De Santis O; Audran R; Pothin E; Warpelin-Decrausaz L; Vallotton L; Wuerzner G; Cochet C; Estoppey D; Steiner-Monard V; Lonchampt S; Thierry AC; Mayor C; Bailer RT; Mbaya OT; Zhou Y; Ploquin A; Sullivan NJ; Graham BS; Roman F; De Ryck I; Ballou WR; Kieny MP; Moorthy V; Spertini F; Genton B
Lancet Infect Dis; 2016 Mar; 16(3):311-20. PubMed ID: 26725450
[TBL] [Abstract][Full Text] [Related]
11. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
[TBL] [Abstract][Full Text] [Related]
12. An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.
Gunale B; Farinola N; Kamat CD; Poonawalla CS; Pisal SS; Dhere RM; Miller C; Kulkarni PS
Lancet Infect Dis; 2024 Jun; 24(6):639-649. PubMed ID: 38408457
[TBL] [Abstract][Full Text] [Related]
13. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Ndiaye BP; Mbaye KD; Thiongane A; Ndour CT; Mboup S; Ake JA; Keshinro B; Akintunde GA; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Hogrefe WR; Günther S; Naficy A; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):707-718. PubMed ID: 32199491
[TBL] [Abstract][Full Text] [Related]
14. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.
Tapia MD; Sow SO; Lyke KE; Haidara FC; Diallo F; Doumbia M; Traore A; Coulibaly F; Kodio M; Onwuchekwa U; Sztein MB; Wahid R; Campbell JD; Kieny MP; Moorthy V; Imoukhuede EB; Rampling T; Roman F; De Ryck I; Bellamy AR; Dally L; Mbaya OT; Ploquin A; Zhou Y; Stanley DA; Bailer R; Koup RA; Roederer M; Ledgerwood J; Hill AVS; Ballou WR; Sullivan N; Graham B; Levine MM
Lancet Infect Dis; 2016 Jan; 16(1):31-42. PubMed ID: 26546548
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Zhu FC; Hou LH; Li JX; Wu SP; Liu P; Zhang GR; Hu YM; Meng FY; Xu JJ; Tang R; Zhang JL; Wang WJ; Duan L; Chu K; Liang Q; Hu JL; Luo L; Zhu T; Wang JZ; Chen W
Lancet; 2015 Jun; 385(9984):2272-9. PubMed ID: 25817373
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.
Beigel JH; Voell J; Kumar P; Raviprakash K; Wu H; Jiao JA; Sullivan E; Luke T; Davey RT
Lancet Infect Dis; 2018 Apr; 18(4):410-418. PubMed ID: 29329957
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.
Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A
Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802
[TBL] [Abstract][Full Text] [Related]
18. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
[TBL] [Abstract][Full Text] [Related]
19. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
